Transplanting Mesenchymal Stem Cells for Treatment of Ischemic Stroke

87Citations
Citations of this article
118Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Stroke is a major disease that leads to high mortality and morbidity. Given the ageing population and the potential risk factors, the prevalence of stroke and socioeconomic burden associated with stroke are expected to increase. During the past decade, both prophylactic and therapeutic strategies for stroke have made significant progress. However, current therapies still cannot adequately improve the outcomes of stroke and may not apply to all patients. One of the significant advances in modern medicine is cell-derived neurovascular regeneration and neuronal repair. Progress in stem cell biology has greatly contributed to ameliorating stroke-related brain injuries in preclinical studies and demonstrated clinical potential in stroke treatment. Mesenchymal stem cells (MSCs) have the differentiating potential of chondrocytes, adipocytes, and osteoblasts, and they have the ability to transdifferentiate into endothelial cells, glial cells, and neurons. Due to their great plasticity, MSCs have drawn much attention from the scientific community. This review will focus on MSCs, stem cells widely utilized in current medical research, and evaluate their effect and potential of improving outcomes in ischemic stroke.

Cite

CITATION STYLE

APA

Wang, F., Tang, H., Zhu, J., & Zhang, J. H. (2018). Transplanting Mesenchymal Stem Cells for Treatment of Ischemic Stroke. Cell Transplantation, 27(12), 1825–1834. https://doi.org/10.1177/0963689718795424

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free